DMAAR - Drugs Made In Amer... Stock Analysis | Stock Taper
Logo
Drugs Made In America Acquisition Corp. Rights

DMAAR

Drugs Made In America Acquisition Corp. Rights NASDAQ
$0.11 -7.41% (-0.01)

Market Cap $2.27 M
52w High $0.12
52w Low $0.11
P/E 0
Volume 4.15K
Outstanding Shares 20.40M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2026 $0 $143.3K $1.97M 0% $0.06 $-143.3K
Q4-2025 $0 $2.09M $212.96K 0% $0.01 $-2.09M
Q3-2025 $0 $263.7K $2.18M 0% $0.07 $-263.7K
Q2-2025 $0 $131.92K $2.29M 0% $0.07 $-131.92K
Q1-2025 $0 $330.93K $1.25M 0% $130.51 $-330.93K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2026 $14.89K $242.04M $7.39M $234.64M
Q4-2025 $6.14K $239.92M $7.28M $232.64M
Q3-2025 $717 $237.63M $7.36M $230.28M
Q2-2025 $822 $235.21M $7.2M $228M
Q1-2025 $923 $232.81M $7.25M $225.56M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2026 $1.97M $-91.25K $0 $100K $8.75K $-91.25K
Q4-2025 $-1.76M $-125.18K $0 $130.6K $5.42K $-125.18K
Q3-2025 $785.09K $137.91K $231.15M $-231.3M $-105 $137.9K
Q2-2025 $3.69M $-300.67K $-231.15M $231.47M $-1.27K $-300.67K
Q1-2025 $1.25M $-251.24K $-231.15M $231.4M $-428 $-251.24K

5-Year Trend Analysis

A comprehensive look at Drugs Made In America Acquisition Corp. Rights's financial evolution and strategic trajectory over the past five years.

+ Strengths

DMAAR currently offers strong liquidity, no financial debt, and a clean capital structure typical of a SPAC, providing a ready pool of capital for the planned transaction. The proposed merger with Power Analytics connects it to a specialized business with proprietary software, patents, and experience in mission-critical power and data environments. If completed, the deal could transform a non-operating shell into a technology-driven enterprise with clear differentiation in digital twins, energy analytics, and quantum-safe cybersecurity.

! Risks

Key risks stem from both structure and execution. As a SPAC, DMAAR has no operating revenue, negative free cash flow, and negative equity, so its current financials do not represent a going business. The value of the rights depends heavily on the successful closing and terms of the merger with Power Analytics, and on the combined company’s ability to execute in a competitive, fast-evolving technology landscape. Additional uncertainties include potential changes in capital structure at closing, integration challenges, and sensitivity to shifts in regulation and cybersecurity threats.

Outlook

Looking ahead, DMAAR’s standalone outlook as a shell company is limited; its future is almost entirely defined by the de-SPAC transaction. If the merger closes as planned and Power Analytics can convert its technology advantages into durable customer contracts and steady cash generation, the combined entity could evolve into a meaningful player in the power analytics and cybersecurity space. At the same time, investors should recognize that the historical financials provide little guidance on future operating performance, and that transaction completion, integration, and market execution will largely determine how the story develops from here.